Skip to content
Screener

Arcus Biosciences RCUS Q3 2025 earnings

Reported October 28, 2025 · After market close

Revenue$26.0MBeat by $1.1M
EPS-$1.27Beat by $0.06
Revenue estimate$24.9M
EPS estimate-$1.33

Next report

Oct 27, 2026 (in a month)
Revenue estimate$11.0M
EPS estimate-$0.89

Financials

Q3 2025

Income statement

See full
Revenue$26.0M-45.8%
Operating income-$142.0M-35.2%
Net income-$135.0M-46.7%
EPS (diluted)-$1.27-27.0%

Balance sheet

See full
Cash & equivalents$238.0M+18.4%
Total debt$111.0M+91.4%
Total equity$436.0M-22.8%
Total assets$974.0M-22.2%

Cash flow

See full
Operating cash flow-$97.0M—
Free cash flow-$97.0M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.45B+3.9%
Enterprise value$1.32B+5.6%
P/S6×+0.7×

Profitability

See full
Operating margin-156.3%+64.5pp
Net margin-142.1%+88.6pp
FCF margin-193.3%—

Returns & leverage

See full
Return on equity-68.1%+39.8pp
Debt / equity0.3×+0.2×
Current ratio3.6×-1.6×

Segments

By segment

See full
Reportable segment$26.0M-45.8%

FAQ

When did Arcus Biosciences report Q3 2025 earnings?
Arcus Biosciences (RCUS) reported Q3 2025 earnings on October 28, 2025 after market close.
What were Arcus Biosciences's Q3 2025 revenue and EPS?
Arcus Biosciences reported revenue of $26.0M and eps of $-1.27 for Q3 2025.
Did Arcus Biosciences beat estimates in Q3 2025?
Revenue beat the consensus estimate of $24.9M by $1.1M. EPS beat the consensus estimate of $-1.33 by $0.06.
How did Arcus Biosciences's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 45.8% from $48.0M a year earlier and eps declined 27.0% from $-1.00.
Where can I find Arcus Biosciences's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001724521-25-000114) and the 10-Q periodic report (0001724521-25-000116) directly on SEC EDGAR. The filing index links above go to sec.gov.